Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationWO2000067787 A3
Type de publicationDemande
Numéro de demandePCT/US2000/012495
Date de publication26 avr. 2001
Date de dépôt5 mai 2000
Date de priorité6 mai 1999
Autre référence de publicationCA2372960A1, CA2372960C, EP1176978A2, WO2000067787A2
Numéro de publicationPCT/2000/12495, PCT/US/0/012495, PCT/US/0/12495, PCT/US/2000/012495, PCT/US/2000/12495, PCT/US0/012495, PCT/US0/12495, PCT/US0012495, PCT/US012495, PCT/US2000/012495, PCT/US2000/12495, PCT/US2000012495, PCT/US200012495, WO 0067787 A3, WO 0067787A3, WO 2000/067787 A3, WO 2000067787 A3, WO 2000067787A3, WO-A3-0067787, WO-A3-2000067787, WO0067787 A3, WO0067787A3, WO2000/067787A3, WO2000067787 A3, WO2000067787A3
InventeursRonald B Moss
DéposantImmune Response Corp Inc, Ronald B Moss
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes:  Patentscope, Espacenet
Hiv immunogenic compositions and methods
WO 2000067787 A3
Résumé
The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
WO1998040100A1 *10 mars 199817 sept. 1998Ottawa Civic Loeb Research InstituteUSE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998055495A2 *5 juin 199810 déc. 1998Dynavax Technologies CorporationImmunostimulatory oligonucleotides, compositions thereof and methods of use thereof
Citations hors brevets
Référence
1 *DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MOSS R B ET AL: "Tumor necrosis factor alpha and human immunodeficiency virus -specific functional immune responses after immunization with Gp120 - depleted, inactivated HIV -1 in incomplete Freund 's adjuvant (REMUNE) in HIV -1-seropositive subjects.", XP002153410, retrieved from STN Database accession no. 1999211139
2 *J HUM VIROL, (1998 JAN-FEB) 1 (2) 77-81.
3 *LANZA P ET AL: "Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 7, 1 April 1998 (1998-04-01), pages 727 - 731, XP004112262, ISSN: 0264-410X
4 *MOSS RONALD B ET AL: "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.", VACCINE, vol. 18, no. 11-12, January 2000 (2000-01-01), pages 1081 - 1087, XP002153409, ISSN: 0264-410X
5 *SUN SIQUAN ET AL: "DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen", JOURNAL OF EXPERIMENTAL MEDICINE,TOKYO,JP, vol. 187, no. 7, 6 April 1998 (1998-04-06), pages 1145 - 1150, XP002148907, ISSN: 0022-1007
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US902884518 sept. 201312 mai 2015Dynavax Technologies CorporationChimeric immunomodulatory compounds and methods of using the same-IV
US93825454 oct. 20135 juil. 2016Coley Pharmaceutical GmbhCpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US959846926 déc. 201321 mars 2017Novartis Vaccines And Diagnostics, Inc.HIV-1 south african subtype C env proteins
Classifications
Classification internationaleA61K39/39, A61P31/18, A61K39/21
Classification coopérativeA61K39/12, C12N2740/16034, A61K2039/57, A61K2039/55566, A61K2039/55572, A61K2039/55505, A61K39/39, A61K39/21, A61K2039/55561, A61K2039/5252
Classification européenneA61K39/21
Événements juridiques
DateCodeÉvénementDescription
16 nov. 2000ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
16 nov. 2000AKDesignated states
Kind code of ref document: A2
Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
10 janv. 2001121Ep: the epo has been informed by wipo that ep was designated in this application
22 févr. 2001DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
26 avr. 2001AKDesignated states
Kind code of ref document: A3
Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
26 avr. 2001ALDesignated countries for regional patents
Kind code of ref document: A3
Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
18 oct. 2001WWEWipo information: entry into national phase
Ref document number: 200108559
Country of ref document: ZA
Ref document number: 2001/08559
Country of ref document: ZA
24 oct. 2001WWEWipo information: entry into national phase
Ref document number: PA/a/2001/010784
Country of ref document: MX
25 oct. 2001WWEWipo information: entry into national phase
Ref document number: 49929/00
Country of ref document: AU
30 oct. 2001ENPEntry into the national phase in:
Ref country code: CA
Ref document number: 2372960
Kind code of ref document: A
Format of ref document f/p: F
Ref document number: 2372960
Country of ref document: CA
30 nov. 2001WWEWipo information: entry into national phase
Ref document number: 2000932163
Country of ref document: EP
6 févr. 2002WWPWipo information: published in national office
Ref document number: 2000932163
Country of ref document: EP
14 mars 2002REGReference to national code
Ref country code: DE
Ref legal event code: 8642
10 févr. 2004NENPNon-entry into the national phase in:
Ref country code: JP